Everest Medicines (HKSE:01952) Receivables Turnover : 4.62 (As of Dec. 2023)

View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines Receivables Turnover?

The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Everest Medicines's Revenue for the six months ended in Dec. 2023 was HK$128.0 Mil. Everest Medicines's average Accounts Receivable for the six months ended in Dec. 2023 was HK$27.7 Mil. Hence, Everest Medicines's Receivables Turnover for the six months ended in Dec. 2023 was 4.62.

Everest Medicines Receivables Turnover Historical Data

The historical data trend for Everest Medicines's Receivables Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines Receivables Turnover Chart

Everest Medicines Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Receivables Turnover

Get a 7-Day Free Trial

1.10

4.86

4.56

Everest Medicines Semi-Annual Data
	Dec18	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Receivables Turnover	Get a 7-Day Free Trial					1.10	2.96	3.98	2.89	4.62

Competitive Comparison of Everest Medicines's Receivables Turnover

For the Biotechnology subindustry, Everest Medicines's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Everest Medicines's Receivables Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Everest Medicines's Receivables Turnover distribution charts can be found below:

* The bar in red indicates where Everest Medicines's Receivables Turnover falls into.

Everest Medicines Receivables Turnover Calculation

Receivables Turnover measures the number of times a company collects its average accounts receivable balance.

Everest Medicines's Receivables Turnover for the fiscal year that ended in Dec. 2023 is calculated as

	Receivables Turnover (A: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (A: Dec. 2023 )	/ (	(Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )
=	137.742	/ (	(5.823	+	54.534)	/	2 )
=	137.742	/	30.1785
=	4.56

Everest Medicines's Receivables Turnover for the quarter that ended in Dec. 2023 is calculated as

	Receivables Turnover (Q: Dec. 2023 )
=	Revenue	/	Average Total Inventories
=	Revenue (Q: Dec. 2023 )	/ (	(Accounts Receivable (Q: Jun. 2023 )	+	Accounts Receivable (Q: Dec. 2023 ))	/	count )
=	128.013	/ (	(0.901	+	54.534)	/	2 )
=	128.013	/	27.7175
=	4.62

Everest Medicines (HKSE:01952) Receivables Turnover Explanation

An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.

Everest Medicines Receivables Turnover Related Terms

Thank you for viewing the detailed overview of Everest Medicines's Receivables Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines (HKSE:01952) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » Receivables Turnover

Comparable Companies

Traded in Other Exchanges

6HN:Germany

Address

1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041

Website

https://www.everestmedicines.com

Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others.

Everest Medicines (HKSE:01952) Headlines

No Headlines